Site Editor

Jennifer R. Brown, MD, PhD


Are B-Cell Receptor Stereotypes Indicative of Patient Outcomes in CLL?

By: Vanessa A. Carter, BS
Posted: Friday, October 14, 2022

During the 2022 Society of Hematologic Oncology (SOHO) Annual Meeting (Abstract EXABS-176-CLL), Kostas Stamatopoulos, MD, PhD, of the Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece, reflected on the clinical significance of B-cell receptors in chronic lymphocytic leukemia (CLL).

Leukemic B cells of patients with CLL were first reported to express certain IGHV genes. Years later, it was discovered these mutations were not random and made up a significant portion of CLL-carried somatic hypermutations. Moreover, this hypermutation status of these genes was found to directly predict the survival of patients in this subset.

Further investigation showed that a high percentage of CLL cases with B-cell receptor immunoglobulin encoded by IGHV3-21 carried almost identical amino acid sequences within the variable heavy complementary determining region 3. In fact, according to the investigators, a recent study of nearly 30,000 participants revealed that 41% of all cases expressed this stereotyped B-cell receptor immunoglobulin.

This finding poses three hypotheses: Certain subsets demonstrate strikingly enriched genomic aberrations; different subsets can exhibit distinct DNA methylation profiles regardless of hypermutation status; and cell signaling via B-cell receptors can be very different between subsets.

Subset #2 remains the largest stereotyped subset of CLL, with B-cell receptor immunoglobulins that are composed of heavy and light chains encoded by genes IGHV3-21 and the IGLV3-21. This subset has a poor clinical outcome, which is independent of somatic hypermutation status, according to the study authors. Furthermore, classification into subset #2 appears to be its own independent prognostic marker for a shorter time to next treatment and progression-free survival.

In contrast, subset #8 harbors B-cell receptors that are encoded by the genes IGHV4-39/IGKV1(D)-39. Individuals in this subset have a 10-fold higher risk for developing Richter’s transformation than other patients with CLL, which is the highest of any subset. Thus, closer follow-up is recommended for this population.

Disclosure: Disclosure information was not provided.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.